ライフサイエンスコーパス: enucleation

1 nths after enucleation, 64.3% >3 years after enucleation).

2 eriod (42 (62 %) eviscerations and 26 (38 %) enucleations).

3 n and pain was achieved in all but 2 eyes (2 enucleations).

4 epithelioma is commonly treated with primary enucleation.

5 r a second opinion after parental refusal of enucleation.

6 ion; however, they display a near absence of enucleation.

7 ents within the critical first 2 years after enucleation.

8 valuated at the time of primary or secondary enucleation.

9 uced erythropoiesis and impaired erythrocyte enucleation.

10 ously published cases have been managed with enucleation.

11 mors with metastasis were large and required enucleation.

12 ize, chromatin and nuclear condensation, and enucleation.

13 layer 2/3 monocular visual cortex following enucleation.

14 quires intensive ocular-salvage treatment or enucleation.

15 urrences in the group primarily treated with enucleation.

16 anscriptome of erythroblasts, prior to their enucleation.

17 ct worse visual outcome and greater risk for enucleation.

18 ve more advanced disease and higher rates of enucleation.

19 uded local resection, radiation therapy, and enucleation.

20 atic disease, or death compared with primary enucleation.

21 observed after esophagectomy versus 0 after enucleation.

22 No eyes were managed with enucleation.

23 s to complications or local recurrence after enucleation.

24 ete nuclear condensation, and lower rates of enucleation.

25 Intravenous blood was collected during enucleation.

26 assembly and remodeling during erythroblast enucleation.

27 d cell maturation at a discrete stage before enucleation.

28 n, in erythroid proliferation, survival, and enucleation.

29 ologies and aberrant F-actin assembly during enucleation.

30 posterior segment toxic effects, or need for enucleation.

31 extensive cellular remodeling that precedes enucleation.

32 tive erythroblast cell-cycle progression and enucleation.

33 esenting the last four cell divisions before enucleation.

34 ng interphase and effectively removed during enucleation.

35 idase (CO) activity patterns after monocular enucleation.

36 undergo dramatic changes during erythroblast enucleation.

37 nhibiting cell size reduction and subsequent enucleation.

38 developed in 3 patients; 1 of them underwent enucleation.

39 esis, was shown to play an essential role in enucleation.

40 oses difficult management and often leads to enucleation.

41 Cellular maturation was maintained including enucleation.

42 y partial lamellar sclerouvectomy (PLSU), or enucleation.

43 went upfront enucleation, and 59 had delayed enucleation.

44 tachment, vitreous hemorrhage, and secondary enucleation.

45 t the need for external beam radiotherapy or enucleation.

46 [IRSS] stage I) were considered for upfront enucleation.

47 8 eyes (75%), and 2 of 8 eyes (25%) required enucleation.

48 trating keratoplasty, and 1 patient required enucleation.

49 trectomy, and 1.6% of BEE patients underwent enucleation.

50 may risk tumor spread compared with primary enucleation.

51 oduced neoadjuvant chemotherapy with delayed enucleation.

52 nomic backgrounds are more likely to receive enucleation.

53 lmos and a high risk of globe rupture during enucleation.

54 rounds would have increased adjusted odds of enucleation.

55 astoma who developed severe PVR and required enucleation.

56 unappreciated role for E2F-2 in erythroblast enucleation.

57 nal detachment (P = 0.01) were predictive of enucleation.

58 ocked terminal erythroid differentiation and enucleation.

59 All patients underwent enucleation.

60 D groups did not differ for time to death or enucleation.

61 espectively, significantly increase prior to enucleation.

62 nce of external-beam radiotherapy (EBRT) and enucleation.

63 years of age and those treated with primary enucleation.

64 cade 2) developed painful glaucoma requiring enucleation.

65 with diffuse T3 disease, underwent secondary enucleation.

66 d infection was exceptionally uncommon after enucleation.

67 which matched the tumor sample postsecondary enucleation.

68 al of 110 (4.4%) patients required secondary enucleation.

69 ere managed by repeat brachytherapy, TTT, or enucleation.

70 keleton, which is ultimately formed prior to enucleation.

71 isk of postirradiation treatment failure and enucleation.

72 ates were comparable to those observed after enucleation.

73 l melanoma, 99 (19%) of which were secondary enucleations.

74 symptoms and possibly reduces the number of enucleations.

75 ces requiring additional treatment and fewer enucleations.

76 external beam radiotherapy (1.4% vs. 1.3%), enucleation (0.9% vs. 0.4%), and observation (48.6% vs.

77 83), central pancreatectomy (13), pancreatic enucleation (10), total pancreatectomy (5), Appleby rese

78 bital enhancement was a common finding after enucleation (100% in the first 3 months after enucleatio

79 outcomes of local recurrence (14% vs. 15%), enucleation (14% vs. 11%), or metastasis (2% vs. 0%) com

80 itreous hemorrhage, 35% (42%); and secondary enucleation, 16% (26%).

81 ned with teletherapy or brachytherapy (14%), enucleation (3%), or observation (21%).

82 observation (29/51, 57%), PLSU (9/51, 18%), enucleation (4/51, 8%), or others (9/51, 18%).

83 med during follow-up (median follow-up after enucleation, 45 months; range, 8-126).

84 nucleation (100% in the first 3 months after enucleation, 64.3% >3 years after enucleation).

85 4%), tumor growth (12/25, 48%), and need for enucleation (7/51, 14%).

86 hstanding the morphological heterogeneity of enucleation across species.

87 ting of neoadjuvant chemotherapy followed by enucleation, adjuvant radiotherapy, and chemotherapy.

88 th eye-preserving radiotherapy compared with enucleation alone, and adding chemotherapy aggravated th

89 children with Rb, including 2 after primary enucleation and 1 undergoing multiple intravitreous inje

90 tients (63 eyes) were primarily treated with enucleation and 72 patients (77 eyes) were primarily tre

91 ound dehiscence in 11.5 % of patients in the enucleation and 9.5 % in the evisceration groups.

92 m ocular rupture and might reduce refusal of enucleation and abandonment.

93 emotherapy can be effective when followed by enucleation and adjuvant chemotherapy.

94 djusted analyses showed associations between enucleation and Asian (OR 2.00, CI 1.08-3.71) or black (

95 edure involving retro-orbital puncture after enucleation and biopsied the frontal lobes and optic ner

96 identify an erythroid-specific regulator of enucleation and elucidate a previously unrecognized mech

97 d surgical outcomes of anophthalmic surgery (enucleation and evisceration) at Jordan University Hospi

98 More efficient enucleation and induction of maturation to an adult phen

99 ormed to analyze associations with secondary enucleation and metastases and Kaplan-Meier estimates to

100 his study suggests that in larger tumors the enucleation and neovascular glaucoma rates might be redu

101 RIK activity promotes efficient erythroblast enucleation and nuclear condensation.

102 However, studies comparing enucleation and partial nephrectomy to date have reveale

103 present a shift in the paradigm of erythroid enucleation and provide novel tools to further study and

104 asis by promoting keratinocyte apoptosis and enucleation and thereby influencing skin immune response

105 rapeutic biopsy on the feasibility of E-GIST enucleation, and (iii) the impact of mucosal ulceration

106 IRSS stage I disease; 102 underwent upfront enucleation, and 59 had delayed enucleation.

107 d scrotal US, contrast-enhanced US, surgical enucleation, and at least 18 months of follow-up.

108 r Kaplan-Meier rates of local tumor relapse, enucleation, and distant metastasis were 3.9%, 3.7%, and

109 Treatment included FNAB, enucleation, and histopathologic analysis.

110 even patients (58%) required evisceration or enucleation, and only 1 patient regained pre-injection v

111 Some authorities advocated prompt enucleation, and others proposed that enucleation promot

112 ion, partial lamellar sclerouvectomy (PLSU), enucleation, and others.

113 large symptomatic melanoma that necessitated enucleation, and the systemic prognosis was poor.

114 Twenty-two of 28 patients underwent enucleation, and viable tumor was present in 21 of 22 en

115 rates of radiation complications, secondary enucleation, and visual acuity outcomes.

116 feasibility and impact on outcomes of tumor enucleation are unknown.

117 included 10 patients who were scheduled for enucleation as primary treatment for uveal melanoma.

118 and in terminal erythroblast maturation and enucleation, as master regulators of the cytoskeleton an

119 One eye underwent enucleation at 6 months, and 1 eye became phthisical 1 y

120 esponded, but 3 of them ultimately underwent enucleation at a median of 8 months (range, 7.9-9.1 mont

121 may improve outcomes of children who undergo enucleation at diagnosis and may avoid unnecessary adjuv

122 In contrast, enucleation at P20 had no significant effect on the call

123 One patient underwent enucleation because of a presumed local tumor recurrence

124 currence and 4 additional patients underwent enucleation because of complications (9.3%).

125 local recurrence, and 16% (n = 21) underwent enucleation because of complications.

126 Three patients (33%) subsequently underwent enucleation because of recurrent tumor and persistent an

127 f patients who had undergone evisceration or enucleation between August 2006 and June 2011.

128 ereye competition is eliminated by monocular enucleation, blocking cholinergic stage II retinal waves

129 ion were 16.6 and 18.0 mm, respectively; for enucleation, both were 20 mm.

130 ere inhibition of chromatin condensation and enucleation but otherwise had little effect on erythroid

131 ythoblasts late in terminal differentiation (enucleation), but the mechanism is largely unexplained.

132 ormal late erythroblasts prior to and during enucleation, but not in Xpo7-knockdown cells.

133 stimate of proportion of patients undergoing enucleation by 5 years was 12.5% (95% confidence interva

134 pective study of patients with UM treated by enucleation by a single ocular oncologist between Novemb

135 use of systemic chemotherapy, and diminished enucleations by 90% without evidence of compromising pat

136 scopy, and with the introduction of surgical enucleation, chemotherapy, and radiation therapy.

137 rived through in vitro differentiation of an enucleation-competent immortalized erythroblast cell lin

138 bles the role played by Hb in erythroid cell enucleation, cytoskeleton maturation, and heme and iron

139 tro and found that absence of Tmod1 leads to enucleation defects in mouse fetal liver erythroblasts,

140 Surprisingly, both cell cycle and enucleation deficits are rescued by epistatic reintroduc

141 Consequently, enucleation did not provide a likely explanation for the

142 otony in 1 eye in the PPV group (that led to enucleation due to phthisis bulbi), and elevated intraoc

143 show significant enhancement of erythroblast enucleation during definitive erythropoiesis.

144 Global nuclear condensation, culminating in enucleation during terminal erythropoiesis, is poorly un

145 ular prognosis with higher need for extended enucleation, exenteration, or both.

146 hree cycles of chemotherapy before scheduled enucleation followed by adjuvant chemotherapy to complet

147 achieved in 10 cases, as 1 patient required enucleation for chronic ocular irritation.

148 in 80 patients (97.6%); 2 patients underwent enucleation for local recurrence.

149 rides over the past century from the days of enucleation for massive, fatal tumor to early detection

150 The odds of undergoing evisceration or enucleation for open-globe injury was highest in host na

151 s, controversy erupted regarding the role of enucleation for PUM.

152 No patients have required secondary enucleation for recurrence or neovascular glaucoma.

153 an alternative to external beam radiation or enucleation for recurrent or refractory vitreous seeds.

154 feasibility of a modified ESD technique with enucleation for removal of gastric subepithelial tumors

155 of 6 days can be an effective alternative to enucleation for residual scleral-invasive conjunctival S

156 ndings in 266 patients who underwent primary enucleation for retinoblastoma were reviewed.

157 Of 403 patients who underwent primary enucleation for the treatment of retinoblastoma, 145 (36

158 Using a modified ESD with enucleation for treatment of gastric subepithelial tumor

159 Data of patients who underwent secondary enucleation for uveal melanoma in the London Ocular Onco

160 Patients undergoing enucleation for uveal melanoma need to be informed of th

161 Indications for secondary enucleations for uveal melanoma were tumor recurrence, n

162 The 5-year enucleation-free survival rate was 94.8% in the endorese

163 ent baseline MR imaging, followed by primary enucleation from 1993 through 2014.

164 ore eyes with iris neovascularization in the enucleation group (25.4%) than in the OAC group (5.2%) a

165 more eyes with group E retinoblastoma in the enucleation group (87.3%) than in the OAC group (29.9%),

166 l recurrence-free survival was worse for the enucleation group (92.1%; 95% CI, 82.0-96.7) than for th

167 risk histopathologic features in the primary enucleation group (P = 0.042), whereas none were found i

168 recurrences (incidence, 7.9%) in the primary enucleation group and 1 orbital recurrence (incidence, 1

169 nful eye secondary to glaucoma (19 %) in the enucleation group and endophthalmitis (28.6 %) in the ev

170 The enucleation group had 5 cases of metastatic disease (7.9

171 In the enucleation group, median tumoral diameter was 40 mm (18

172 es were 50% and 25% in the esophagectomy and enucleation groups, respectively, with 2 postoperative d

173 Enucleation has largely been superseded by various forms

174 However, the process of erythroblast enucleation has remained provocative and poorly understo

175 inal detachment [RD] >1 quadrant), timing to enucleation, histopathologic features, and follow-up.

176 evacizumab, plaque radiotherapy, and primary enucleation in 1 patient because of painful neovascular

177 cluded plaque radiotherapy in 4 patients and enucleation in 1 patient; 1 patient refused therapy.

178 or control in 87%, poor visual acuity in 9%, enucleation in 13% (for reasons of tumor recurrence [n =

179 at plaque implantation in 279 (31.7%), post-enucleation in 225 (25.6%), and post-resection/pre-laser

180 developed in 17% of patients and resulted in enucleation in 4% of patients.

181 patch graft in 14% of patients (10/73), and enucleation in 5% of patients (4/73).

182 glaucoma was the leading cause of secondary enucleation in 78 of the 2499 patients (3.1%).

183 treatment was surgical for 16 patients, with enucleation in 8 and esophagectomy in 8.

184 ars), scheduled to undergo planned uniocular enucleation in an institutional setting, were randomly d

185 l to evaluate orbital tumor recurrence after enucleation in children with retinoblastoma.

186 l in 87% of patients at 6 years and avoiding enucleation in most cases.

187 comycin or levofloxacin eye drops leading to enucleation in one case.

188 mon predisposing factor for evisceration and enucleation in our tertiary care center followed by blin

189 dered as a safe and efficient alternative to enucleation in patients with large choroidal melanoma, a

190 at I-125 EPBT offers a viable alternative to enucleation in patients with local recurrence of PUM, yi

191 e of erythroblasts and a reduced erythrocyte enucleation in their BM compared to littermate controls.

192 d completion of mouse and human erythroblast enucleation in vivo.

193 that sieve element differentiation involves enucleation, in which the nuclear contents are released

194 Factors related to enucleation included diabetes mellitus, poor initial vis

195 After unilateral enucleation, increased GCC and pRNFL thicknesses were de

196 Visual deprivation through binocular enucleation induces a synapse-specific and depth-depende

197 The median diagnosis to enucleation interval was 4 days (range, 0-14 days).

198 d expanded in the last year, suggesting that enucleation is a form of asymmetric cell division.

199 dis et al provide evidence that erythroblast enucleation is a more complex and multistep process than

200 In conclusion, enucleation is a multistep process that resembles cytoki

201 scleral invasion or intraocular involvement, enucleation is advised.

202 In addition, enucleation is an acceptable method for management, part

203 ical techniques, however, the indication for enucleation is no longer determined by posttrauma NLP vi

204 Enucleation is performed by following the natural plane

205 poorly to local resection and in most cases enucleation is required.

206 ar management including plaque radiotherapy, enucleation, local resection, or laser therapy.

207 Rates of neovascular glaucoma (NVG) and enucleation (mainly for local recurrence or NVG) were 27

208 Enucleation may be required due to poor vision and inabi

209 Monocular enucleation (ME) drastically affects the contralateral v

210 In adult mice, monocular enucleation (ME) results in an immediate deactivation of

211 been no recurrence, extrascleral extension, enucleation, metastasis, or death.

212 of 5 months postradiotherapy, necessitating enucleation (n = 2) or orbital exenteration (n = 2).

213 Primary tumor treatment included enucleation (n = 21, 60%), tumor removal by PLSU (n = 8,

214 adiotherapy (n = 1) for localized disease or enucleation (n =3) for extensive tumor hemorrhage (n = 1

215 (n=60) or proton beam radiation (n=2), with enucleation necessary in 26 patients.

216 oskeletal mechanisms underlying erythroblast enucleation, notwithstanding the morphological heterogen

217 poiesis, Trim58 expression, dynein loss, and enucleation occur concomitantly, and all are inhibited b

218 chnique can save eyes otherwise destined for enucleation, ocular salvage may be accompanied by local

219 travitreous melphalan (10-20 mug) in 4 eyes, enucleation of 1 eye, and local observation while receiv

220 pact of macrophages on the proliferation and enucleation of erythroblasts from healthy individuals an

221 f differentiation is inherently critical for enucleation of erythroid precursors, thereby demonstrati

222 was to evaluate the feasibility of surgical enucleation of esophageal gastrointestinal stromal tumor

223 ic kinases have specialized roles supporting enucleation of maturing erythroblasts.

224 actors associated with treatment failure and enucleation of plaqued eyes were evaluated using Cox pro

225 The distribution, maturation, and enucleation of primitive erythroblasts were also impaire

226 stage glaucoma in patient 2 resulted in the enucleation of the eye, which on histology demonstrated

227 vaporization of the prostate, Holmium laser enucleation of the prostate, and vaporization of the pro

228 objectives evaluated (i) the impact of tumor enucleation on oncological outcomes, (ii) the effect of

229 We also estimated the effect of enucleation on the surface areas of striate and extrastr

230 Patients treated with enucleation only evidenced the greatest decline in cogni

231 pected, as was the poorer performance of the enucleation-only group.

232 Patients who underwent either enucleation or esophagectomy were compared.

233 eal dexamethasone reduced the requirement of enucleation or evisceration (p = 0.01).

234 ogistic regression model was performed using enucleation or evisceration and primary open-globe repai

235 id not receive systemic steroids required an enucleation or evisceration due to a blind, painful eye.

236 nd the sixty-seven that did not; however, no enucleation or evisceration was required in patients rec

237 019) invasion and a higher need for extended enucleation or exenteration (27% vs. 11%; P < 0.001).

238 atients received radical resection by either enucleation or hepatic resection, while the remaining 8

239 Radiotherapy, chemotherapy, enucleation, or observation.

240 derwent intervention with excisional biopsy, enucleation, or orbital exenteration.

241 r HIV, conjuntival excision biopsy, extended enucleation, orbital exenteration.

242 odal protocol with neoadjuvant chemotherapy, enucleation, orbital external-beam radiotherapy, and adj

243 manageable complications and fewer secondary enucleations over time for these large melanomas.

244 detected significantly more after secondary enucleation (P = 0.048).

245 Enucleation, plaque radiotherapy, local resection, or th

246 prompt enucleation, and others proposed that enucleation promoted metastasis, known as the "Zimmerman

247 me to distant failure, local failure, death, enucleation, radiation retinopathy, optic neuropathy, an

248 eceived neoadjuvant chemotherapy followed by enucleation, radiotherapy, and adjuvant chemotherapy.

249 and involves strategically chosen methods of enucleation, radiotherapy, chemotherapy, laser photocoag

250 Enucleation rates decreased over time across all racial,

251 Enucleation rates decreased over time.

252 mor recurrence, visual acuity, and secondary enucleation rates were analyzed and compared between gro

253 hthalmos and those with a perceived risk for enucleation refusal and/or abandonment were given two to

254 Treatment abandonment because of enucleation refusal is a limitation of improving outcome

255 en (6.3%) who underwent primary or secondary enucleation, respectively.

256 Significantly increased enucleation risk was associated with older age at diagno

257 E-GIST enucleation seems safe for tumors of less than 65 mm in

258 No enucleation specimen contained tumor cells within sclera

259 icted LR histopathologic features at primary enucleation, suggesting safe trial eye salvage.

260 shed between 2003 and 2017 on outcomes after enucleation surgeries in which a variety implants were u

261 as of treatment-naive patients who underwent enucleation surgery for choroidal malignant melanomas.

262 mplants resulted in excellent motility after enucleation surgery, although many studies did not asses

263 of the studies did not assess motility after enucleation surgery, and the 7 that did evaluate this me

264 rates of porous and nonporous implants after enucleation surgery.

265 Once enucleation techniques were perfected, the majority of c

266 we identified a family of genes required for enucleation that encode proteins with nuclease domains.

267 ic mice, and Hb Null erythroid cells undergo enucleation to form reticulocytes.

268 patients with a lag time >1 month and no pre-enucleation treatment (P = 0.007 and P = 0.010, respecti

269 characteristics, including lag time and pre-enucleation treatment status.

270 ocular pain improved with sildenafil, making enucleation unnecessary.

271 ured retinoblastoma patients and, also after enucleation using spectral domain optical coherence tomo

272 n survival for patients randomly assigned to enucleation versus brachytherapy.

273 Mean follow-up after enucleation was 20.4 months (range 9.9-31.7).

274 Enucleation was carried out in 14 patients (9.5%) becaus

275 the early stage of terminal erythropoiesis, enucleation was decreased.

276 ee groups; 15 unilateral RB patients in whom enucleation was indicated as a sole treatment performed

277 Enucleation was necessary in 3 of 20 eyes (15%).

278 Enucleation was necessary in 9 (24%) cases for recurrenc

279 Primary enucleation was performed and histopathologic features n

280 Evisceration or enucleation was performed in 16 (25%) patients.

281 Primary enucleation was performed in 33.3% of patients and was m

282 An enucleation was performed, and an intraocular tumor comp

283 Dia2, a Rho effector known to play a role in enucleation, was also found essential for erythroblast c

284 for patients undergoing upfront and delayed enucleation were 0.89 +/- 0.03 and 0.68 +/- 0.06, respec

285 Higher rates of enucleation were associated with low educational attainm

286 reated for a retinoblastoma or who underwent enucleation were excluded.

287 Risk factors for enucleation were greater tumor thickness, closer proximi

288 Younger patients at enucleation were more likely to report pain (t = 4.13; d

289 Patients studied sooner after enucleation were more likely to report seeing (Mann-Whit

290 Local treatment failure and enucleation were relatively infrequent events after I(12

291 ients with primary uveal melanoma treated by enucleation were reviewed.

292 Indications for secondary enucleation were tumor recurrence in 60 (61%), neovascul

293 Enucleations were indicated only in case of re-recurrenc

294 During the study period 515 enucleations were performed for uveal melanoma, 99 (19%)

295 acquire a dumbbell-shaped morphology during enucleation, whereas human bone marrow erythroblast nucl

296 r distal pancreatic resections or gastrinoma enucleation with lymphadenectomy, 2 patients also had sy

297 ixty consecutive patients undergoing primary enucleation with no adjuvant chemotherapy or radiation w

298 (Reese-Ellsworth group V) treated by primary enucleation with or without adjuvant therapy depending o

299 l and signaling requirements of erythroblast enucleation with the cytokinesis process have been confi

300 tment failure was the most common reason for enucleation within 3 years of treatment; beyond 3 years,